Post-Traumatic Stress Disorder Market

Market Overview: 

The 7 major post-traumatic stress disorder markets reached a value of US$ 1.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.2 Billion by 2034, exhibiting a growth rate (CAGR) of 5.18% during 2024-2034.

The post-traumatic stress disorder market has been comprehensively analyzed in IMARC's new report titled "Post-Traumatic Stress Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Post-traumatic stress disorder (PTSD) refers to a mental health condition characterized by a range of symptoms that persist for an extended period of time, causing significant discomfort and impairing daily functioning. Some of the indications include intrusive thoughts or memories of the traumatic event, flashbacks, nightmares, and intense distress when exposed to reminders of the trauma. Various avoidance behaviors, such as avoiding certain places, activities, conversations, etc., related to the trauma are common. Individuals suffering from PTSD may experience negative changes in mood and cognition, including feelings of guilt or shame, diminished interest in activities, distorted beliefs about themselves or the world, etc. Hyperarousal indications, such as difficulty sleeping, irritability, hypervigilance, exaggerated startle response, etc., are also prevalent. The diagnostic process typically includes a comprehensive evaluation of the patient's symptoms and medical history. The clinician will use the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) to determine if the indications meet the criteria for a PTSD prognosis. The assessment may involve interviews, questionnaires, and psychological evaluations to gather information and make an accurate diagnosis.

The increasing cases of direct trauma exposure, which include experiencing or witnessing situations like combat, sexual assault, natural disasters, accidents, serious injuries, etc., are primarily driving the post-traumatic stress disorder market. Moreover, the rising prevalence of numerous associated risk factors, such as pre-existing mental health conditions, certain personality traits, including a tendency to experience heightened levels of anxiety, alterations in the stress response system, etc., is further creating a positive outlook for the market. Besides this, the widespread adoption of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) to alleviate various symptoms, such as anxiety, depression, sleep disturbances, etc., is acting as another significant growth-inducing factor. Furthermore, the escalating usage of eye movement desensitization and reprocessing (EMDR) therapy, which involves bilateral stimulation, including eye movements, auditory tofnes, tapping, etc., for facilitating the processing and integration of traumatic experiences, thereby lowering their emotional impact, is also bolstering the market growth. Additionally, the emerging popularity of mindfulness-based interventions that focus on cultivating present-moment awareness, non-judgmental acceptance, and self-compassion while helping patients regulate emotions, reduce rumination as well as improve overall well-being is expected to drive the post-traumatic stress disorder market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the post-traumatic stress disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for post-traumatic stress disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the post-traumatic stress disorder market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the post-traumatic stress disorder market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the post-traumatic stress disorder market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current post-traumatic stress disorder marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the post-traumatic stress disorder market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the post-traumatic stress disorder market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the post-traumatic stress disorder market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of post-traumatic stress disorder across the seven major markets?
• What is the number of prevalent cases (2018-2034) of post-traumatic stress disorder by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of post-traumatic stress disorder by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with post-traumatic stress disorder across the seven major markets?
• What is the size of the post-traumatic stress disorder patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of post-traumatic stress disorder?
• What will be the growth rate of patients across the seven major markets?
   

Post-Traumatic Stress Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for post-traumatic stress disorder drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the post-traumatic stress disorder market?
• What are the key regulatory events related to the post-traumatic stress disorder market?
• What is the structure of clinical trial landscape by status related to the post-traumatic stress disorder market?
• What is the structure of clinical trial landscape by phase related to the post-traumatic stress disorder market?
• What is the structure of clinical trial landscape by route of administration related to the post-traumatic stress disorder market?